Close Menu

Neurological & Psychological Disorders

News on research and diagnostic developments in neuroscience.

The company said that it will use the funds to build out its CLIA facility and continue developing its blood-based Alzheimer's disease test for the clinic.

The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.

Invitae will provide free genetic testing on a 53-gene panel and counseling to patients suspected of having an LSD to facilitate earlier diagnosis and appropriate treatment.

The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.

The company posted Q4 revenues of $15.9 million, up from $10.9 million in Q4 2018, and beat the consensus Wall Street estimate of $14.2 million.